These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 17145931)
21. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. Lalonde MS; Lobritz MA; Ratcliff A; Chamanian M; Athanassiou Z; Tyagi M; Wong J; Robinson JA; Karn J; Varani G; Arts EJ PLoS Pathog; 2011 May; 7(5):e1002038. PubMed ID: 21625572 [TBL] [Abstract][Full Text] [Related]
22. Modulation of RNA function by oligonucleotides recognizing RNA structure. Toulmé JJ; Di Primo C; Moreau S Prog Nucleic Acid Res Mol Biol; 2001; 69():1-46. PubMed ID: 11550792 [TBL] [Abstract][Full Text] [Related]
23. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Arzumanov A; Stetsenko DA; Malakhov AD; Reichelt S; Sørensen MD; Babu BR; Wengel J; Gait MJ Oligonucleotides; 2003; 13(6):435-53. PubMed ID: 15025911 [TBL] [Abstract][Full Text] [Related]
24. An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Mehiri M; Upert G; Tripathi S; Di Giorgio A; Condom R; Pandey VN; Patino N Oligonucleotides; 2008 Sep; 18(3):245-56. PubMed ID: 18707540 [TBL] [Abstract][Full Text] [Related]
25. Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Boulme F; Perälä-Heape M; Sarih-Cottin L; Litvak S Biochim Biophys Acta; 1997 Apr; 1351(3):249-55. PubMed ID: 9130587 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region. Brown DE; Arzumanov A; Syed S; Gait MJ; Lever AM Antivir Chem Chemother; 2006; 17(1):1-9. PubMed ID: 16542000 [TBL] [Abstract][Full Text] [Related]
27. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. Crombez L; Morris MC; Heitz F; Divita G Methods Mol Biol; 2011; 764():59-73. PubMed ID: 21748633 [TBL] [Abstract][Full Text] [Related]
28. Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription. Lee R; Kaushik N; Modak MJ; Vinayak R; Pandey VN Biochemistry; 1998 Jan; 37(3):900-10. PubMed ID: 9454580 [TBL] [Abstract][Full Text] [Related]
29. Discoveries of Tat-TAR interaction inhibitors for HIV-1. Yang M Curr Drug Targets Infect Disord; 2005 Dec; 5(4):433-44. PubMed ID: 16535863 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of HIV-1 Tat-TAR interaction by diphenylfuran derivatives: effects of the terminal basic side chains. Gelus N; Bailly C; Hamy F; Klimkait T; Wilson WD; Boykin DW Bioorg Med Chem; 1999 Jun; 7(6):1089-96. PubMed ID: 10428378 [TBL] [Abstract][Full Text] [Related]
32. Multivalent binding oligomers inhibit HIV Tat-TAR interaction critical for viral replication. Wang D; Iera J; Baker H; Hogan P; Ptak R; Yang L; Hartman T; Buckheit RW; Desjardins A; Yang A; Legault P; Yedavalli V; Jeang KT; Appella DH Bioorg Med Chem Lett; 2009 Dec; 19(24):6893-7. PubMed ID: 19896372 [TBL] [Abstract][Full Text] [Related]
33. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Jing N Expert Opin Investig Drugs; 2000 Aug; 9(8):1777-85. PubMed ID: 11060776 [TBL] [Abstract][Full Text] [Related]
34. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors. Tramontano E; Onidi L; Esposito F; Badas R; La Colla P Biochem Pharmacol; 2004 May; 67(9):1751-61. PubMed ID: 15081874 [TBL] [Abstract][Full Text] [Related]
36. Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. Fraternale A; Paoletti MF; Casabianca A; Orlandi C; Millo E; Balestra E; Damonte G; Perno CF; Magnani M J Drug Target; 2009 May; 17(4):278-85. PubMed ID: 19255894 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Richter S; Parolin C; Gatto B; Del Vecchio C; Brocca-Cofano E; Fravolini A; Palù G; Palumbo M Antimicrob Agents Chemother; 2004 May; 48(5):1895-9. PubMed ID: 15105155 [TBL] [Abstract][Full Text] [Related]
38. Synthetic access to spacer-linked 3,6-diamino-2,3,6-trideoxy-alpha-D-glucopyranosides--potential aminoglycoside mimics for the inhibition of the HIV-1 TAR-RNA/Tat-peptide complex. Jöge T; Jesberger M; Bröker P; Kirschning A Carbohydr Res; 2007 Sep; 342(12-13):1704-14. PubMed ID: 17562328 [TBL] [Abstract][Full Text] [Related]
39. Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery. Chavali SS; Bonn-Breach R; Wedekind JE J Biol Chem; 2019 Jun; 294(24):9326-9341. PubMed ID: 31080171 [TBL] [Abstract][Full Text] [Related]
40. Oligonucleotides as inhibitors of human immunodeficiency virus. Field AK Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]